Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05364450 · ClinicalTrials.gov registry record · NA
Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors
A NA study, sponsored by Indiana University.
- Completed
- Registry status
- NA
- Development phase
- 390
- Enrollment target
NCT05364450: Completed NA study, sponsored by Indiana University.
NCT05364450 is a NA study that has completed, run by Indiana University. The registered enrollment target is 390 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05364450, a NA study, has completed, sponsored by Indiana University.
- COMPLETED
- Registry status
- NA
- Development phase
- 390 participants
- Enrollment target
Study Summary
Fear of cancer recurrence (FCR) is a highly prevalent, disruptive, and under-treated problem for breast cancer survivors. This randomized controlled trial will test the efficacy of group-based Acceptance and Commitment Therapy compared to Cognitive Behavioral Therapy and enhanced usual care for breast cancer survivors suffering from FCR while examining its cost-effectiveness and the mechanisms by which the intervention may work. Study findings will guide the future care of breast cancer survivors with FCR.
Primary Outcome
The 43-item Fear of Cancer Recurrence Inventory (FCRI) includes triggers, psychological distress, coping strategies, reassurance seeking, insight, severity, and functional impairments subscales. Each item is rated on a scale from 0 (never, not at all, or I don't think about it) to 4 (all the time or a great deal), participants indicate the extent to which they are fearful, with higher scores indicating greater FCR.
Interventions
- BEHAVIORAL Enhanced Usual Care
- BEHAVIORAL Cognitive Behavioral Therapy
- BEHAVIORAL Acceptance Commitment Therapy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2021-08-17 |
| Est. Completion | 2024-07-09 |
| Phase | NA |
What the finished NCT05364450 record still lists
NCT05364450 is an interventional study that assigns participants to a tested intervention. The registered 390 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (72% lower).
The record links to 0 conditions, and to 3 interventions - of which Enhanced Usual Care is the first listed.
NCT05364450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05364450 about?
NCT05364450 is a clinical study titled "Facilitating Adaptive Coping With Fear of Recurrence Among Breast Cancer Survivors". Fear of cancer recurrence (FCR) is a highly prevalent, disruptive, and under-treated problem for breast cancer survivors. This randomized controlled trial will test the efficacy of group-based Acceptance and Commitment Therapy compared to Cognitive Behavioral Therapy and enhanced usual care for brea...
What is the current status of trial NCT05364450?
This trial is currently completed. It is a NA study. The enrollment target is 390 participants. The study started on 2021-08-17. Estimated completion is 2024-07-09.
What interventions are being tested in trial NCT05364450?
The interventions under investigation include: Enhanced Usual Care (BEHAVIORAL), Cognitive Behavioral Therapy (BEHAVIORAL), Acceptance Commitment Therapy (BEHAVIORAL).
Who is sponsoring clinical trial NCT05364450?
This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05364450's enrollment target sits among peer trials
390 269th of 2000 higher than 1,731 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00397111 · 390 participants
Development of Magnetic Resonance Imaging Techniques for Studying Mood and Anxiety Disorders
- NCT05335928 · 390 participants · Phase 3
Abatacept in Immune Checkpoint Inhibitor Myocarditis
- NCT05445960 · 390 participants · NA
Correlation Between Intraoperative Tourniquet Use and Limb pH, Functional Measures and Patient-reported Outcomes After Ankle Fracture Surgery
- NCT05997615 · 390 participants · Phase 1
Safety, Pharmacokinetics, and Preliminary Efficacy of VIR-5500 (AMX-500) in Prostate Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI